Drug Trial Radar · NCT02297945
Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
Last checked: Nov 20, 2026Latest source record: Sep 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Apr 2015
Primary completion
Nov 2019
Study completion Apr 29, 2020
Sponsor
- Lead sponsor
- HRA PharmaIndustry
- Sponsor type
- Industry
- First posted
- Nov 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment.
Conditions
- Cushing's Syndrome
Interventions
metyraponeDrug
Single arm study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Normalization of cortisol levels (urinary free cortisol)Time frame: 3 months
Locations
36 sites in 8 countries. Site status is shown where the registry gives one.
University hospital Antwerp
Antwerp, Belgium
CHU Erasme
Brussels, Belgium
University hospital Saint Luc
Brussels, Belgium
CHU Liège
Liège, Belgium
Charité Berlin
Berlin, Germany
Universitätsklinikum Essen
Essen, Germany
Munich university
Munich, Germany
University hospital Wuerzburg
Würzburg, Germany
State health center
Budapest, Hungary
Semmelweis Egyetem II. Belgyógyászati Klinika
Budapest, Hungary
University Debrecen
Debrecen, Hungary
University of Pecs
Pécs, Hungary
University of Szeged
Szeged, Hungary
Grande Ospedale Metropolitano Niguarda
Milan, Italy
Ospedale San Luca IRCCS Istituto Auxologico Italiano
Milan, Italy
S. Giuseppe Hospital
Milan, Italy
Federico II University
Naples, Italy
University of Padova
Padova, Italy
University of Turin
Turin, Italy
San Luigi Gonzaga Hospital, University of Turin
Orbassano, Turin, Italy
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
Gliwice, Poland
University Hospital
Krakow, Poland
University Clinical Hospital
Wroclaw, Poland
Institutul National de Endocrinologie 'C.I Parhon' - Endocrinologie II
Bucharest, Romania
Institutul National de Endocrinologie 'C.I Parhon' - Endocrinologie VI
Bucharest, Romania
Spitalul Universitar de Urgenta Militar Central 'Dr Carol Davila'
Bucharest, Romania
Spitalul Clinic Judetean de Urgenta Cluj-Napoca
Cluj-Napoca, Romania
S.C Centrul Clinic Mediquest SRL
Sângeorgiu de Mureş, Romania
Spitalul Clinic Judetean de Urgenta Sibiu
Sibiu, Romania
Spitalul Clinic Judetean Mures
Târgu Mureş, Romania
University hospital clinic of Barcelona
Barcelona, Spain
Hospital Universitario La Ribera
Valencia, Spain
Ankara Numune Training and Research Hospital
Ankara, Turkey (Türkiye)
Dokuz Eylul UMF
Izmir, Turkey (Türkiye)
Ondokuz Mayıs University Medical Faculty
Samsun, Turkey (Türkiye)
Karadeniz Teknik University
Trabzon, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.